Cabaletta Bio, Inc. (CABA)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Steven Nichtberger
Employees:
50
2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104
(267) 759-3100
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|